GlassScriptPhysician profile
Tamara B Wyse
NPI 1881609642
$6,433.74
in general payments reported to CMS, 2019-2025
17 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,279 · 2020: $473 · 2021: $302 · 2022: $349 · 2023: $183 · 2024: $2,383 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,801 · Food and Beverage: $1,190 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,801.48 |
| Food and Beverage | $1,190.35 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,549.75 | 2019-2025 | Lensx, Centurion, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $1,808.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $480.19 | 2019-2023 | |
| New World Medical,INC. | $479.65 | 2020-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Allergan, INC. | $268.81 | 2019-2021 | |
| Lumenis Be INC | $145.11 | 2025 | M22 |
| Rayner Intraocular Lenses Limited | $142.91 | 2024 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Ocular Therapeutix, INC. | $140.30 | 2021-2025 | Dextenza |
| Harrow Eye, LLC | $98.15 | 2024 | Vevye |
| Rxsight INC | $73.77 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Aerie Pharmaceuticals, INC. | $69.32 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.34 | 2019 | |
| Abbvie INC. | $46.16 | 2022 | |
| Shire North American Group INC | $44.81 | 2019 | |
| Bausch & Lomb Americas INC. | $20.83 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Wyse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.